Archived Newsletters
-
10.08.25 -- Execute Or Decay: Radiopharma's Outsourcing Reality
10/8/2025
10/08/25 Outsourced Pharma Newsletter
-
10.07.25 -- Novel Preclinical Models To Advance Oncology Therapeutics
10/7/2025
10/07/25 Outsourced Pharma Newsletter
-
10.07.25 -- Process Development Strategies For Lyophilized Products
10/7/2025
10/07/25 Outsourced Pharma Newsletter
-
10.07.25 -- What FDA's Complete Response Letters (CRL) Say About Outsourcing
10/7/2025
10/07/25 Outsourced Pharma Newsletter
-
10.06.25 -- Accelerating Cell & Gene Therapies With End-To-End CDMO Solutions
10/6/2025
10/06/25 Outsourced Pharma Newsletter
-
10.06.25 -- STREAM Edition: Advice For Managing Multiple CDMOs
10/6/2025
10/06/25 Outsourced Pharma Newsletter
-
10.06.25 -- You're In Charge Of Strategic Sourcing? What's That Actually Mean?
10/6/2025
10/06/25 Outsourced Pharma Newsletter
-
10.03.25 -- End-To-End Support For Biologic API And Drug Product Development
10/3/2025
10/03/25 Outsourced Pharma Newsletter
-
10.03.25 -- Why Pharma, Medical Device Risks Must Be Analyzed By Their Risk Mechanisms
10/3/2025
10/03/25 Outsourced Pharma Newsletter
-
10.02.25 -- New Podcast Episodes: Tackling Alzheimer's Disease, Dye Drug Conjugates For Cancer, FDA Fridays
10/2/2025
10/02/25 Outsourced Pharma Newsletter